A start-up enterprise, spun-off from Tufts University labs, creating bio-electrical treatments for regenerating limbs and tissue, is raising $8 million in new seed funds. . . . → Read More: Bio-Electric Regeneration Company Adds $8M in Seed Funds
|
|||||
       |
 Comments are closed  Finance, New products  biomedical, biotechnology, engineering, entrepreneurs, equity, investment, life sciences, materials science, mathematics, pharmaceuticals, physical sciences, preclinical, U.K., university, venture capital 
Tests with lab mice show low doses of an experimental oral drug can selectively kill prostate cancer cells while not affecting surrounding healthy tissue. . . . → Read More: Biotech Drug Shown to Kill Prostate Tumor Cells Comments are closed New products biomedical, biotechnology, cancer, chemistry, entrepreneurs, life sciences, pharmaceuticals, preclinical, university 
In a preclinical test, thyroid tissue earlier removed from lab animals was re-implanted in a protective pouch, which generates production of key hormones by the animals. . . . → Read More: Implanted Tissue Shown to Produce Thyroid Hormones Comments are closed New products biomedical, biotechnology, Canada, cancer, life sciences, medical device, preclinical, university 
A biotechnology company creating products for gut health and a university immunology lab are evaluating cleaning products for potential damage to human protective tissues. . . . → Read More: Biotech, Academic Lab Partner on Microbiome-Safe Products Comments are closed Joint ventures/collaborations, New products biomedical, biotechnology, chemistry, Europe, health care, life sciences, preclinical, university 
A vaccine against gonorrhea given as a nasal spray is shown to generate protective immune responses in lab mice of both sexes, and in females similar to an intravaginal vaccine. . . . → Read More: Nasal Spray Vaccine Shown to Stop Gonorrhea Infections Comments are closed Joint ventures/collaborations, New products biomedical, biotechnology, chemistry, Europe, licensing, life sciences, NIH, pharmaceuticals, physical sciences, preclinical, university 
A bioengineering team devised techniques for feasibly adding cancer-killing enzymes to engineered immune cells that in lab mice kill solid-tumor and blood cancer cells. . . . → Read More: Nanotech Enzyme Process Boosts T-Cell Cancer Therapies Comments are closed New products biomedical, biotechnology, cancer, chemistry, engineering, life sciences, manufacturing, materials science, nanotechnology, pharmaceuticals, physical sciences, preclinical, university 
An enterprise discovering new drugs with optical light-based protein chemistry is emerging from stealth, including work with biopharmaceutical company Genentech. . . . → Read More: Protein Chemistry Biotech Gains Collaboration, Venture Funds 2 comments - (Comments are closed) Finance, Joint ventures/collaborations, New products biomedical, biotechnology, cancer, chemistry, entrepreneurs, equity, investment, life sciences, mathematics, pharmaceuticals, physical sciences, preclinical, university 
Engineers and neuroscientists developed a circuit that in lab mice connects implanted lab-grown brain tissue to the brain’s cognitive center and responds to visual stimuli. . . . → Read More: Implanted Organoid Connects to Brain, Reacts to Visual Cues Comments are closed New products biomedical, computer science, engineering, life sciences, materials science, medical device, physical sciences, preclinical, semiconductors, stem cells, university 
An experiment is underway testing a bone repair biomaterial in lab mice under weightless conditions on the International Space Station. . . . → Read More: Bone Regeneration Experiment Begun on Space Station Comments are closed Joint ventures/collaborations, New products biomedical, biotechnology, life sciences, materials science, pharmaceuticals, physical sciences, preclinical, space, stem cells, university 
(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/) 31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger Comments are closed Finance biomedical, biotechnology, clinical trials, entrepreneurs, equity, investment, IPO, life sciences, merger, pharmaceuticals, preclinical |
||||
|
Copyright © 2024 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
RSS - Posts
You must be logged in to post a comment.